Skip to main content

NANOCOMPOSITES BLANDOS Y FUNCIONALES A BASE DE POLIMEROS NATURALES PARA LA REGENERACION DE TEJIDOS

PID2021-122645OB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2021
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Otros (Other)

Advances in Conductive Nanomaterials for Cardiac Arrhythmia and Future Directions in Bioevaluation Strategies

  • Srinivasan, Sumithra Y.
  • Laromaine, Anna
Cardiac arrhythmia (CA), characterized by irregular heart rhythms, affects nearly 90% of individuals with cardiovascular diseases. Commonly triggered by myocardial infarction (MI) or ion channel dysfunctions, CA is traditionally treated using pacemakers, cardioversion, ablation, and anti-arrhythmic drugs. Recently, emerging strategies like cardiac patches and injectable formulations with conductive nanomaterials (CNMs) have shown promise in restoring cardiac rhythm post-MI. This review explores CNMs-such as gold nanoparticles, carbon nanotubes, and conjugated polymers-that mimic the electrical and mechanical properties of native cardiac tissue. While in vitro studies show encouraging results, translating CNMs to clinical settings faces challenges. Few studies have assessed their safety and efficacy in rodent models, and none in larger animals. This gap stems from the complexity and ethical hurdles of large animal research. To address this, the review advocates using small animal models like zebrafish, Drosophila melanogaster, and Caenorhabditis elegans. These models offer insights into pharmacokinetics, pharmacodynamics, genetic effects, and cardiac parameters such as ejection fraction and cardiac output-data often unattainable in vitro. Such platforms can better evaluate CNMs' safety and efficacy than 2D/3D cultures, accelerating progress toward clinical application., This work was supported by the Spanish Ministry of Science and Innovation (MICINN) through the National Research Agency (AEI) and European Regional Development Funds (ERDF/FEDER), project BIOSOFT-REGE ref PID2021-122645OB-I00, BACTIVE ref PID2024-1576370B-I00, BIOCCHIP ref PDC2023-145826-I00, the Program/Generalitat de Catalunya (2021SGR00446 project), the Severo Ochoa Program of the Spanish Ministry of Science and Innovation (MICINN_Grant CEX2018−000,789-S, CEX2023-001263-S), and the projects FIP-BEAT, and the PDC2022-133755-I00/AEI/10.13039/501100011033 European Union NextGeneration EU/PRTR. This research was also supported by the European Union's Horizon 2020 research and innovation program H2020-MSCA-COFUND-2016 (DOC-FAM, Grant Agreement No. 754397), European Union’s Horizon Europe research and innovation program under grant agreement No 101057527 (NextGEM). Authors participate in the Spanish National Research Council (CSIC) interdisciplinary platform for sustainable plastics toward a circular economy (SusPlast), and in CSIC-Conexion Nanomedicina del CSIC, EPNOE network, and Red Nanocare 2.0, Grant RED2022-134560-T funded by MCIN/AEI/10.13039/501100011033. The authors acknowledge the use of Biorender.com., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2023-001263-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Otros (Other)

A Comprehensive Review of Clinical Studies on Bacterial Cellulose: From the Earliest Uses to Contemporary Innovations

  • Meslier, Thomas
  • D'Antin, Justin Christopher
  • Julio, Gemma
  • Roig Serra, Anna
Bacterial cellulose (BC), a biopolymer produced by Gram-negative bacteria such as those from the Komagataeibacter genus, has emerged as a promising material in biomedical applications due to its exceptional purity, biocompatibility, mechanical strength, versatility in sterilization, biodegradability, and sustainable production. This comprehensive review traces the evolution of BC-based medical products from their initial development in the 1980s to present-day innovations, highlighting the progression of clinical evidence supporting their use. Early clinical studies primarily focused on BC as a temporary skin substitute for burns and ulcers. Over time, the scope of BC applications expanded to include dural defect repair, tympanic membrane reconstruction, and fetal surgery for spina bifida. The quality of clinical evidence has improved, with recent years seeing an increase in randomized controlled trials and larger patient cohorts. Several BC-based products are already commercially available, supported by regulatory approvals and a growing body of clinical data. This review seeks to serve as a valuable resource by providing an exhaustive recapitulation of published clinical studies on BC-based medical devices encompassing 3,857 subjects and offering insights into their efficacy, safety, and regulatory considerations. The review outlines future research directions to validate BC's potential across a wide range of in vivo biomedical applications., The authors want to acknowledge the Generalitat de Catalunya (grants 2021SGR00446, 2019LLAV00046, 2021PRO00204, and 2023INNOV00044). The projects PID2021-122645OBI00 and the “Severo Ochoa” Program for the Center of Excellence in R&D (CEX2023001263-S), funded by MCIN/AEI/10.13039/501100011033 by “ERDF A way of making Europe”., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2023-001263-S)., Peer reviewed